CXCR3/CD183/GPR9 recombinant proteins and antibodies

C-X-C Chemokine Receptor Type 3 (CXCR3), also known as CD183 or GPR9, is a chemokine receptor primarily expressed on T-cells, playing a critical role in regulating immune responses and inflammatory processes. CXCR3 mediates the migration of immune cells by binding to its ligands (such as CXCL9, CXCL10, and CXCL11), which is crucial in inflammation and immune response. CXCR3 is involved in the pathogenesis of various immune diseases, cancers, and infectious diseases. Its overexpression has been linked to autoimmune diseases, immune evasion, and metastasis in tumors, making CXCR3 a promising therapeutic target.

The activation of CXCR3 is closely related to the progression of several diseases. In the tumor immune microenvironment, CXCR3 plays a pivotal role in the interaction between tumor cells and immune cells. Studies show that excessive activation of CXCR3 can promote tumor cell migration and immune evasion. In contrast, inhibiting CXCR3 helps restore immune function and enhances immune surveillance against tumors. Therefore, developing drugs targeting CXCR3 has become a key focus in the field of immunotherapy.

Currently, drug development targeting CXCR3 is mainly focused on small molecule inhibitors and antibodies. Small molecule inhibitors work by blocking the binding of CXCR3 to its ligands, thereby suppressing the migration and activation of immune cells, which can be used to treat immune-related diseases and cancer. Additionally, anti-CXCR3 antibodies are being developed to directly interfere with CXCR3 function and regulate immune responses. As the understanding of CXCR3’s role in tumor immune evasion deepens, CXCR3-targeted therapies are expected to become a new option in immunotherapy in the coming years.

To assist in the development of CXCR3 targeted therapies, DIMA BIOTECH can now provide a full range of products and services for CXCR3 targets. Products include active CXCR3 recombinant proteins, full-length CXCR3 proteins, CXCR3 reference antibodies, and FC-verified monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization, and affinity maturation services. In addition, to accelerate the development of CXCR3 biotherapy, DIMA BIOTECH has also prepared a CXCR3 target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple CXCR3 IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.